Search NASA⌕ Search

Engineering topics

Wu, Huali

Publications and source records attributed to Wu, Huali.

4 records
All sourcesNASA NTRSDOE OSTI
DOE OSTI2021

An investigation of the phase behaviors for quaternary U-Nb/Mo-Ti-Zr metallic fuel alloys

We report quaternary fuel alloys containing U, Nb/Mo, Ti, and Zr are proposed as fuel candidates for sodium-cooled fast reactors (SFRs). In this work, two Nb-bearing alloys, i.e., U-NT5Z (U-2.5Nb-2.5Ti-5.0Zr in wt%) and U-NT7Z (U-1.5Nb-1.5Ti-7.0Zr in wt%), and two Mo-bearing alloys, i.e., U-MT5Z (U-2.5Mo-2.5Ti-5.0Zr in wt%) and U-MT7Z (U-1.5Mo-1.5Ti-7.0Zr in wt%) were characterized and compared. The characterization techniques were differential scanning calorimetry (DSC), X-ray powder diffraction (XRD), and scanning electron microscopy/energy dispersive X-ray spectroscopy (SEM/EDS). DSC was performed to obtain the transition behaviors, and XRD and SEM/EDS were applied for phase identification. The results were combined to obtain the solid-state phase transitions between 500 °C and 850 °C for the alloys. It is found that the Nb-bearing alloys comprise similar phase transition behaviors as the Mo-bearing alloys. The phase transitions in U-NT5Z are a →γ at 608 °C and U 2 Ti → γ at 627 °C, which are ~40 °C higher than that of U-MT5Z. The phase transition in U-NT7Z is a → γ at 645 °C, and is 23 °C higher than that of U-MT7Z.

11 NUCLEAR FUEL CYCLE AND FUEL MATERIALS↗
DOE OSTI2021

Solid-state phase transitions of two quaternary metallic fuel alloys (U-2.5Mo-2.5Ti-5.0Zr and U-1.5Mo-1.5Ti-7.0Zr in wt. %)

This study focuses on the solid-state phase transitions of two quaternary fuel alloys for fast reactors: U-1.5Mo-1.5Ti-7.0Zr (U-MT7Z) and U-2.5Mo-2.5Ti-5.0Zr (U-MT5Z). Here, the phase transitions were determined by differential scanning calorimetry (DSC), X-ray powder diffraction (XRD), and scanning electron microscopy/energy dispersive X-ray spectroscopy (SEM/EDS). To identify the high temperature phases, the alloys were annealed at 873K, 948K, 1023K, and 1123K (all under 72 hours). Combining those characterizations, the phase transitions are determined. In U-MT7Z, there is one phase transition observed, and it is ascribed to α + U 2 Ti → γ transition. In U-MT5Z, two transitions are found. The first transition is α → γ, while the second is U 2 Ti → γ. The γ phase onset temperature of U-MT5Z is lower than that of U-MT7Z due to the higher Mo content.

11 NUCLEAR FUEL CYCLE AND FUEL MATERIALS↗
DOE OSTI2020

Estimation of Body Fat Percentage for Clinical Pharmacokinetic Studies in Children

Obesity is a prevalent childhood condition and the degree of adiposity appears likely to be an important covariate in the pharmacokinetics (PKs) of many drugs. We undertook these studies to facilitate the evaluation and, where appropriate, quantification of the covariate effect of body fat percentage (BF%) on PK parameters in children. We examined two large databases to determine the values and variabilities of BF% in children with healthy body weights and in those with obesity, comparing the accuracy and precision of BF% estimation by both clinical methods and demographically derived techniques. Additionally, we conducted simulation studies to evaluate the utility of the several methods for application in clinical trials. BF% was correlated with body mass index (BMI), but was highly variable among both children with healthy body weights and those with obesity. Bio‐impedance and several demographically derived techniques produced mean estimates of BF% that differed from dual x‐ray absorptiometry by < 1% (accuracy) and a SD of 5% or less (precision). Simulation studies confirmed that when the differences in precision among the several methods were small compared with unexplained between‐subject variability of a PK parameter, the techniques were of similar value in assessing the contribution of BF%, if any, as a covariate for that PK parameter. The combination of sex and obesity stage explained 68% of the variance of BF% with BMI. The estimation of BF% from sex and obesity stage can routinely be applied to PK clinical trials to evaluate the contribution of BF% as a potential covariate.

Green, Thomas P.↗